Subscribe to Journal
Get full journal access for 1 year
We are sorry, but there is no personal subscription option available for your country.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok JL et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 2005; 105: 324–334.
Huettner CS, Zhang P, Van Etten RA, Tenen DG . Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet 2000; 24: 57–60.
Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780–3792.
Zhang X, Ren R . Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood 1998; 92: 3829–3840.
Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA . The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med 1999; 189: 1399–1412.
Daley GQ, Van Etten RA, Baltimore D . Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci USA 1991; 88: 11335–11338.
Hu Y, Liu Y, Pelletier S, Buchdunger E, Warmuth M, Fabbro D et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004; 36: 453–461.
Krause DS, Van Etten RA . Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model. Blood 2004; 104: 4236–4244.
Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B et al. JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling. Exp Hematol 2007; 35: 1695–1703.
Cui Y, Riedlinger G, Miyoshi K, Tang W, Li C, Deng CX et al. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol Cell Biol 2004; 24: 8037–8047.
Dai X, Chen Y, Di L, Podd A, Li G, Bunting KD et al. Stat5 is essential for early B cell development but not for B cell maturation and function. J Immunol 2007; 179: 1068–1079.
Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci USA 2006; 103: 1000–1005.
Li G, Wang Z, Zhang Y, Kang Z, Haviernikova E, Cui Y et al. STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp Hematol 2007; 35: 1684–1694.
Walz C, Ahmed W, Lazarides K, Betancur M, Patel N, Hennighausen L et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 2012; 119: 3550–3560.
Taichman RS, Reilly MJ, Emerson SG . Human osteoblasts support human hematopoietic progenitor cells in vitro bone marrow cultures. Blood 1996; 87: 518–524.
Visnjic D, Kalajzic Z, Rowe DW, Katavic V, Lorenzo J, Aguila HL . Hematopoiesis is severely altered in mice with an induced osteoblast deficiency. Blood 2004; 103: 3258–3264.
Stier S, Ko Y, Forkert R, Lutz C, Neuhaus T, Grunewald E et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005; 201: 1781–1791.
Calvi LM, Sims NA, Hunzelman JL, Knight MC, Giovannetti A, Saxton JM et al. Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. J Clin Invest 2001; 107: 277–286.
Krause DS, Fulzele K, Catic A, Sun CC, Dombkowski D, Hurley MP et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat Med 2013; 19: 1513–1517.
Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758–764.
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature 2008; 453: 110–114.
Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470–480.
Roberts KG, Morin RD, Zhang J, Hirst M, Zhao Y, Su X et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 2012; 22: 153–166.
Joshi I, Yoshida T, Jena N, Qi X, Zhang J, Van Etten RA et al. Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia. Nat Immunol 2014; 15: 294–304.
The symposium and publication of this supplement were sponsored by the Division of Hematology/Oncology at the Warren Alpert Medical School of Brown University and NIH Center of Biomedical Research Excellence (COBRE) for Stem Cells Biology at Rhode Island Hospital. RVE was supported by grant from TEVA Pharmaceuticals.
RVE has received consulting fees from Pfizer Inc. and Acerta Pharma.
About this article
Cite this article
Van Etten, R. Insights into the pathophysiology and therapy of myeloproliferative neoplasms from mouse models. Leukemia Suppl 3, S27–S28 (2014). https://doi.org/10.1038/leusup.2014.15
- TKI resistance
- mouse models of CML
- PPR mice
- IKZF1 mutation